Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS)-Reference-Cited by-同舟云学术

Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS)

Published:2019-01-17 Issue:7 Volume:35 Page:1139-1148
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Foley Catherine¹,Tundia Namita²,Simpson Eric³,Teixeira Henrique D.²,Litcher-Kelly Leighann¹,Bodhani Amit²

Affiliation:

1. Patient-Centered Outcomes, Adelphi Values USA, Boston, MA, USA;

2. Health Economics and Outcomes Research, AbbVie, North Chicago, IL, USA;

3. School of Medicine, Oregon Health and Science University, Portland, OR, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1560222

Reference27 articles.

1. Atopic Dermatitis: Global Epidemiology and Risk Factors

2. National Eczema Association. Atopic dermatitis. NEA; 2016 [cited 2016 July 7]. San Rafael, California, USA. Available from: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis-2/.

3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Who has atopic dermatits? NIAMSD; 2013 [cited 2016 July 7]. Bethesda, Maryland, USA. Available from: http://www.niams.nih.gov/health_info/atopic_dermatitis/#b.

4. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross‐sectional burden‐of‐illness study in atopic dermatitis (MEASURE‐AD) in Australia and New Zealand reveals impacts on well‐being;Australasian Journal of Dermatology;2024-05-21

2. Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study;Journal of Dermatological Treatment;2024-05-02

3. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2);Dermatology and Therapy;2024-05

4. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2);American Journal of Clinical Dermatology;2024-03-25

5. Burden of Disease in Real-Life Setting of Patients With Atopic Dermatitis: Italian Data From the MEASURE-AD Study;Dermatology Practical & Conceptual;2024-01-31